US incentive scheme for neglected diseases: a good idea gone wrong?

The US priority review voucher scheme was intended to encourage drug companies to invest in treatments for neglected diseases. But nearly seven years on, as Peter Doshi reports, there is little demonstrated innovation and evidence that the benefits are not going where they were intended